

[Letterhead of the organisation]

Henning Gädeke
c/o Michael Makanga
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d’Or
1060 Brussels
Belgium

[Date]

Letter of endorsement

Dear Sir/Madam,

On behalf of Delft Imaging Systems BV, registered at Wiltonstraat 41, Veenendaal 3905KW, The Netherlands, under [VAT number], and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

Delft Imaging Systems BV is an innovative company specializing in the development and implementation of advanced diagnostic imaging solutions, with a particular focus on expanding access to high-quality tuberculosis screening. The company has pioneered the use of digital X-ray technologies and artificial intelligence applications to deliver cost-effective and scalable diagnostic tools in low-resource settings. Delft Imaging works extensively with governments, NGOs, and healthcare providers to implement solutions that are sustainable and adapted to local contexts. Its commitment to bridging technological innovation with practical health system needs has established it as a trusted partner in global TB control efforts. In advancing equitable access to modern diagnostics, Delft Imaging’s objectives are closely aligned with the Global Health EDCTP3 Joint Undertaking’s mission to accelerate innovation and improve health outcomes in high-burden regions.

Delft Imaging Systems BV functions as co-applicant (partner number 5) in the AddiCAD 2nd stage proposal which is currently in preparation (Proposal acronym: AddiCAD, proposal number 101248855-2, topic: HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage.) To enable the implementation of the proposed project, the consortium offers to make significant own investments. On project level these amount to a total of € 387 500 (i.e. an additional 18.5% on top of the requested EC contribution) and will be made in the form of in-kind contributions to operational activities (IKOP) as defined in Article 2.8 of the EDCTP3 JU’s founding regulation (Single Basic Act, SBA).

Specifically, the contribution of Delft Imaging Systems BV will include the placement of 3 CAD4TBboxes in South Africa, Namibia and the Gambia, incl software license and service support for the duration of the project as well as software/AI development, as described in Task 2.2 “Clinical evaluation of AddiCAD” of the proposal.

Commented [AM1]: Is this detailed enough?

This commitment will not only allow for more work to be done in the scope of the AddiCAD project, but also have the secondary effect of increasing the budget of Global Health EDCTP JU, in accordance with Article 103 of the SBA, and make possible the funding of more research projects.

[Letterhead of the organisation]

We estimate the total value of this in-kind contribution to the AddiCAD project by Delft Imaging Systems BV to be EUR 81 250.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,

[Date, name and signature of the authorised representative]